Baystreet Staff - Thursday, September 10, 2026 Oncolytics Biotech Inc 10:15 AM EST - Oncolytics Biotech Inc : Today announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. Oncolytics Biotech Inc shares N.ONCY are trading up one cent at $0.80. Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=8494479386447356
